[1]
Kim, J.U.; Shariff, M.I.F.; Crossey, M.M.E.; Gomez-Romero, M.; Holmes, E.; Cox, I.J.; Fye, H.K.S.; Njie, R.; Taylor-Robinson, S.D. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J. Hepatol., 2016, 8(10), 471-484.
[2]
Zhen, C.; Zhu, C.; Chen, H.; Xiong, Y.; Tan, J.; Chen, D.; Li, J. Systematic analysis of molecular mechanisms for HCC metastasis via text mining approach. Oncotarget, 2017, 8(8), 13909-13916.
[3]
Varnholt, H.; Drebber, U.; Schulze, F.; Wedemeyer, I.; Schirmacher, P.; Dienes, H.P.; Odenthal, M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 2008, 47(4), 1223-1232.
[4]
Tsai, C.C.; Huang, K.W.; Chen, H.F.; Zhan, B.W.; Lai, Y.H.; Lee, F.H.; Lin, C.Y.; Ho, Y.C.; Chao, Y.W.; Su, Y.C.; Jane, S.W.; Chen, Y.C.; Hsu, C.I.; Li, P.H.; Hsu, H.C.; Suzuki, Y.; Sugano, S.; Lin, J.Y. Gene expression analysis of human hepatocellular carcinoma by using full-length cDNA library. J. Biomed. Sci., 2006, 13(2), 241-249.
[5]
Wee, P.; Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers., 2017, 9(5), 52.
[6]
Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Kempf, C.R.; Long, J.; Laidler, P.; Mijatovic, S.; Maksimovic-Ivanic, D.; Stivala, F.; Mazzarino, M.C.; Donia, M.; Fagone, P.; Malaponte, G.; Nicoletti, F.; Libra, M.; Milella, M.; Tafuri, A.; Bonati, A.; Bäsecke, J.; Cocco, L.; Evangelisti, C.; Martelli, A.M.; Montalto, G.; Cervello, M.; McCubrey, J.A. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany N.Y.), 2011, 3(3), 192-222.
[7]
Li, L.; Zhao, G.D.; Shi, Z.; Qi, L.L.; Zhou, L.Y.; Fu, Z.X. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol. Lett., 2016, 12(5), 3045-3050.
[8]
Huerta-Yepez, S.; Yoon, N.K.; Hernandez-Cueto, A.; Mah, V.; Rivera-Pazos, C.M.; Chatterjee, D.; Vega, M.I.; Maresh, E.L.; Horvath, S.; Chia, D.; Bonavida, B.; Goodglick, L. Expression of phosphorylated Raf Kinase Inhibitor Protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer, 2011, 11(1), 259.
[9]
Akyol, G.; Yilmaz, G. Stem cell expression profile in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Stem Cell Transl. Investig., 2014, 1(1), 14232.
[10]
Guo, L.; Zhou, D.; Pryse, K.M.; Okunade, A.L.; Su, X. Fatty acid 2-hydroxylase mediates diffusional mobility of Raft-associated lipids, GLUT4 level, and lipogenesis in 3T3-L1 adipocytes. J. Biol. Chem., 2010, 285(33), 25438-25447.
[11]
Daniels, V.W.; Smans, K.; Royaux, I.; Chypre, M.; Swinnen, J.V.; Zaidi, N. Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. PLoS One, 2014, 9(9), e106913.
[12]
Beloribi-Djefaflia, S.; Vasseur, S.; Guillaumond, F. Lipid metabolic reprogramming in cancer cells. Oncogenesis, 2016, 5, e189.
[13]
Malik, S.; Bhatnagar, S.; Chaudhary, N.; Katare, D.P.; Jain, S. DEN+ 2-AAF-induced multistep hepatotumorigenesis in wistar rats: Supportive evidence and insights. Protoplasma, 2013, 250(1), 175-183.
[14]
Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 1976, 72(1), 248-254.
[15]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25(4), 402-408.
[16]
Chatr-aryamontri, A.; Oughtred, R.; Boucher, L.; Rust, J.; Chang, C.; Kolas, N.K.; O’Donnell, L.; Oster, S.; Theesfeld, C.; Sellam, A.; Stark, C.; Breitkreutz, B.J.; Dolinski, K.; Tyers, M. The BioGRID interaction database: 2017 update. Nucleic Acids Res., 2017, 45(Database issue), D369-D379.
[17]
Ranjpour, M.; Katare, D.P.; Wajid, S.; Jain, S.K. HCC specific protein network involving interactions of EGFR with A-Raf and transthyretin: Experimental analysis and computational biology correlates. Anticancer. Agents Med. Chem., 2018, 18(8), 1163-1176.
[18]
Schmidt-Arras, D.; Rose-John, S. IL-6 pathway in the liver: From physiopathology to therapy. J. Hepatol., 2016, 64(6), 1403-1415.
[19]
Tian, G.; Mi, J.; Wei, X.; Zhao, D.; Qiao, L.; Yang, C.; Li, X.; Zhang, S.; Li, X.; Wang, B. Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization. Sci. Rep., 2015, 5, 11394.
[20]
Naugler, W.E.; Karin, M. The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med., 2008, 14(3), 109-119.
[21]
Alderson, N.L.; Hama, H. Fatty acid 2-hydroxylase regulates cAMP-induced cell cycle exit in D6P2T schwannoma cells. J. Lipid Res., 2009, 50(6), 1203-1208.
[22]
Alderson, N.L.; Rembiesa, B.M.; Walla, M.D.; Bielawska, A.; Bielawski, J.; Hama, H. The human FA2H gene encodes a fatty acid 2-hydroxylase. J. Biol. Chem., 2004, 279(47), 48562-48568.
[23]
Colombino, M.; Sperlongano, P.; Izzo, F.; Tatangelo, F.; Botti, G.; Lombardi, A.; Accardo, M.; Tarantino, L.; Sordelli, I.; Agresti, M.; Abbruzzese, A.; Caraglia, M.; Palmieri, G. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from south Italy. Cell Death Dis., 2012, 3(1), e259.
[24]
Tannapfel, A.; Sommerer, F.; Benicke, M.; Katalinic, A.; Uhlmann, D.; Witzigmann, H.; Hauss, J.; Wittekind, C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut, 2003, 52(5), 706-712.
[25]
Lee, J.W.; Soung, Y.H.; Kim, S.Y.; Park, W.S.; Nam, S.W.; Min, W.S.; Kim, S.H.; Lee, J.Y.; Yoo, N.J.; Lee, S.H. Mutational analysis of the ARAF gene in human cancers. APMIS, 2005, 113(1), 54-57.
[26]
Moretti, L.; Tchernin, L.; Scapozza, L. Tyrosine kinase drug discovery: What can be learned from solved crystal structures? ARKIVOC, 2006, 8, 38-49.
[27]
Rauch, J.; O’Neill, E.; Mack, B.; Matthias, C.; Munz, M.; Kolch, W.; Gires, O. Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res., 2010, 70(4), 1679-1688.
[28]
Rauch, J.; Kolch, W. Spatial regulation of ARAF controls the MST2-Hippo pathway. Small GTPases, 2017, 1-6.
[29]
Matallanas, D.; Birtwistle, M.; Romano, D.; Zebisch, A.; Rauch, J.; von Kriegsheim, A.; Kolch, W. Raf family kinases: Old dogs have learned new tricks. Genes Cancer, 2011, 2(3), 232-260.
[30]
Mazurek, S.; Drexler, H.C.; Troppmair, J.; Eigenbrodt, E.; Rapp, U.R. Regulation of pyruvate kinase type M2 by A-Raf: A possible glycolytic stop or go mechanism. Anticancer Res., 2007, 27(6b), 3963-3971.
[31]
Borisov, N.; Aksamitiene, E.; Kiyatkin, A.; Legewie, S.; Berkhout, J.; Maiwald, T.; Kaimachnikov, N.P.; Timmer, J.; Hoek, J.B.; Kholodenko, B.N. Systems-level interactions between insulin–EGF networks amplify mitogenic signaling. Mol. Syst. Biol., 2009, 5, 256-256.
[32]
Ferreira, I.G.; Pucci, M.; Venturi, G.; Malagolini, N.; Chiricolo, M.; Dall’Olio, F. Glycosylation as a main regulator of growth and death factor receptors signaling. Int. J. Mol. Sci., 2018, 19(2), E580.
[33]
Knowlden, J.M.; Jones, H.E.; Barrow, D.; Gee, J.M.W.; Nicholson, R.I.; Hutcheson, I.R. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res. Treat., 2008, 111(1), 79-91.
[34]
Laplante, M.; Sabatini, D.M. An emerging role of mTOR in lipid biosynthesis. Curr. Biol., 2009, 19(22), R1046-R1052.
[35]
Caillot, F.; Hiron, M.; Goria, O.; Gueudin, M.; Francois, A.; Scotte, M.; Daveau, M.; Salier, J.P. Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. Am. J. Pathol., 2009, 175(1), 46-53.
[36]
Sousa, M.M.; Berglund, L.; Saraiva, M.J. Transthyretin in high density lipoproteins: Association with apolipoprotein A-I. J. Lipid Res., 2000, 41(1), 58-65.
[37]
Liz, M.A.; Gomes, C.M.; Saraiva, M.J.; Sousa, M.M. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J. Lipid Res., 2007, 48(11), 2385-2395.
[38]
Katare, D.P.; Malik, S.; Mani, R.J.; Ranjpour, M.; Jain, S.K. Novel mutations in transthyretin gene associated with hepatocellular carcinoma. Mol. Carcinog., 2017, 57(1), 70-77.
[39]
Sethakorn, N.; Dulin, N.O. RGS expression in cancer: Oncomining the cancer microarray data. J. Recep. Sig. Trans., 2013, 33(3), 166-171.
[40]
Bjarnadottir, O.; Kimbung, S.; Johansson, I.; Veerla, S.; Jonsson, M.; Bendahl, P.O.; Grabau, D.; Hedenfalk, I.; Borgquist, S. Global transcriptional changes following statin treatment in breast cancer. Clin. Cancer Res., 2015, 21(15), 3402-3411.
40
3